DE60026538D1 - Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen - Google Patents

Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen

Info

Publication number
DE60026538D1
DE60026538D1 DE60026538T DE60026538T DE60026538D1 DE 60026538 D1 DE60026538 D1 DE 60026538D1 DE 60026538 T DE60026538 T DE 60026538T DE 60026538 T DE60026538 T DE 60026538T DE 60026538 D1 DE60026538 D1 DE 60026538D1
Authority
DE
Germany
Prior art keywords
treatment
clavulanic acid
pharmaceutical preparations
neurological disorders
derivatives contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026538T
Other languages
English (en)
Other versions
DE60026538T2 (de
Inventor
A Koppel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REVAAX PHARMACEUTICALS IND LLC
Original Assignee
REVAAX PHARMACEUTICALS IND LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REVAAX PHARMACEUTICALS IND LLC filed Critical REVAAX PHARMACEUTICALS IND LLC
Application granted granted Critical
Publication of DE60026538D1 publication Critical patent/DE60026538D1/de
Publication of DE60026538T2 publication Critical patent/DE60026538T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
DE60026538T 1999-08-16 2000-08-16 Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlung von neurologischen störungen Expired - Lifetime DE60026538T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14911599P 1999-08-16 1999-08-16
US149115P 1999-08-16
US17245299P 1999-12-17 1999-12-17
US172452P 1999-12-17
US17657000P 2000-01-18 2000-01-18
US176570P 2000-01-18
US19453400P 2000-04-04 2000-04-04
US194534P 2000-04-04
PCT/US2000/022434 WO2001012171A2 (en) 1999-08-16 2000-08-16 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases

Publications (2)

Publication Number Publication Date
DE60026538D1 true DE60026538D1 (de) 2006-05-04
DE60026538T2 DE60026538T2 (de) 2007-02-01

Family

ID=27495857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026538T Expired - Lifetime DE60026538T2 (de) 1999-08-16 2000-08-16 Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlung von neurologischen störungen

Country Status (14)

Country Link
US (5) US6610681B1 (de)
EP (3) EP2305251A3 (de)
JP (2) JP5049437B2 (de)
CN (1) CN1382047A (de)
AT (2) ATE319447T1 (de)
AU (2) AU781218B2 (de)
BR (1) BR0013366A (de)
CA (3) CA2746824A1 (de)
DE (1) DE60026538T2 (de)
DK (1) DK1206261T3 (de)
ES (1) ES2258980T3 (de)
MX (1) MXPA02001667A (de)
NZ (1) NZ517663A (de)
WO (2) WO2001012171A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
CA2746824A1 (en) * 1999-08-16 2001-01-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
AU2001291499B2 (en) * 2000-09-29 2007-02-08 Nucor Corporation A method of producing steel
US20030013635A1 (en) * 2001-04-11 2003-01-16 Meyerhoff James L. Method for the treatment of depression by inhibition of NAALADase
JP2004532475A (ja) 2001-05-15 2004-10-21 サイコジェニックス・インコーポレーテッド 行動情報工学を監視するシステムおよび方法
WO2002102378A1 (en) * 2001-06-18 2002-12-27 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1474151A4 (de) * 2002-01-17 2010-03-03 R E D Lab N V Verfahren zur behandlung von chronischen immunkrankheiten
EP1485078B1 (de) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran zur Behandlung von Reizdarmsyndrom
WO2004030633A2 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040191803A1 (en) * 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
KR20050115245A (ko) * 2003-02-26 2005-12-07 존스 홉킨스 유니버시티 글루타메이트 운반 조절 화합물 및 방법
BRPI0413908A (pt) * 2003-08-25 2006-10-24 Revaax Pharmaceuticals Llc formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo
US20070238717A1 (en) * 2003-10-21 2007-10-11 Johns Hopkins University Neuroprotection with Beta-Lactam Compounds
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
PT2982372T (pt) 2005-04-05 2020-10-09 Univ Yale Agentes moduladores do glutamato no tratamento de distúrbios mentais
US8048874B2 (en) * 2005-07-19 2011-11-01 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
CA2702257C (en) * 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
AU2008317315A1 (en) * 2007-10-26 2009-04-30 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
WO2010118361A1 (en) * 2009-04-09 2010-10-14 Sopharmia, Inc. Beta lactamase inhibitors
WO2010127125A1 (en) * 2009-04-29 2010-11-04 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
WO2013006808A2 (en) * 2011-07-06 2013-01-10 Rexahn Pharmaceuticals, Inc. Clavulanic acid for treatment of restless legs syndrome
WO2013014496A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
KR101738210B1 (ko) * 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
AU2012311050A1 (en) 2011-09-21 2014-03-06 Stem Cell Medicine Ltd. Beta-lactam compounds for treating diabetes
WO2013042122A1 (en) 2011-09-21 2013-03-28 Cohen Irun R Beta-lactam compounds for enhancing t cell -mediated immune responses
US9770423B2 (en) 2012-07-22 2017-09-26 Indiana University Research And Technology Corporation Modulation sAPP, sAAPα and BDNF levels in individuals diagnosed with FXS and ASD
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
DK2968352T3 (da) 2013-03-12 2019-01-02 Gladius Pharmaceuticals Corp Derivatiserede 3-styryl-cephalosporiner
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
EP3058371B1 (de) 2013-10-14 2021-06-16 Indiana University Research and Technology Corporation Verwendung von acamprosat zur modulierung der erk-1 2-aktivierung bei tiermodellen für fxs und asd und mit fxs und asd diagnostizierten personen
DK3122743T3 (da) 2014-03-28 2023-02-20 Azevan Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
WO2017218697A1 (en) * 2016-06-17 2017-12-21 The Trustees Columbia University In The City Of New York Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans
CN111295373A (zh) 2017-09-15 2020-06-16 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
CN108522431A (zh) * 2018-04-03 2018-09-14 葛仟鸿 抗生素对果蝇记忆认知影响用测定方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3986882A4 (de) * 2019-06-24 2023-04-05 Diverse Biotech, Inc. Beta-lactam-cannabinoid-konjugatmoleküle
CN112843034B (zh) * 2019-11-26 2022-08-23 亚瑟瑞智科技管理顾问股份有限公司 包含克拉维酸与丙戊酸的组合物及其用途
WO2022102801A1 (ko) * 2020-11-10 2022-05-19 김현기 오배자 추출물 및 암피실린을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 및 치료용 조성물
CN114767690B (zh) * 2022-06-22 2022-08-23 中国中医科学院中药研究所 头孢噻吩酸在制备抗抑郁药物中的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
CA1085392A (en) * 1976-03-25 1980-09-09 Masayuki Narisada Arylmalonamido-1-oxadethiacephalosporins
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4234579A (en) * 1977-06-07 1980-11-18 Pfizer Inc. Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4268503A (en) 1978-09-14 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4302503A (en) * 1978-05-17 1981-11-24 Libbey-Owens-Ford Company Architectural spandrel
US4349672A (en) * 1979-11-29 1982-09-14 Hoffmann-La Roche Inc. Cephalosporin derivatives
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
US4594247A (en) 1981-12-21 1986-06-10 Eli Lilly And Company Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4824850A (en) 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US5008257A (en) 1982-05-18 1991-04-16 University Of Florida Brain-specific drug delivery
US4880921A (en) 1982-05-18 1989-11-14 University Of Florida Brain-specific drug delivery
US5187158A (en) 1982-05-18 1993-02-16 University Of Florida Brain-specific drug delivery
US4900837A (en) 1982-05-18 1990-02-13 University Of Florida Brain-specific drug delivery of steroid sex hormones cleaved from pyridinium carboxylates and dihydro-pyridine carboxylate precursors
JPS59104389A (ja) * 1982-12-06 1984-06-16 Shionogi & Co Ltd オキサセファム誘導体
JPS59225182A (ja) * 1983-03-25 1984-12-18 Yamanouchi Pharmaceut Co Ltd ２−アゼチジノン−４−カルボン酸の誘導体
US4628077A (en) 1983-12-16 1986-12-09 The Standard Oil Company Preparation of polyamide with catalyst comprising transition metal attached to a ligand which contains electron withdrawing groups
US5082853A (en) 1984-02-29 1992-01-21 Bodor Nicholas S Brain-specific analogues of centrally acting amines
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US4771059A (en) 1984-02-29 1988-09-13 University Of Florida Brain-specific analogues of centrally acting amines
JPS62106015A (ja) * 1985-10-31 1987-05-16 Sumitomo Pharmaceut Co Ltd 抗痴呆薬
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5552543A (en) 1988-12-14 1996-09-03 Simon Fraser University Six-membered hetero "N" compounds
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
GB9201639D0 (en) * 1992-01-25 1992-03-11 Smithkline Beecham Plc Pharmaceutical formulations
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
CA2151714C (en) * 1993-10-20 2005-10-11 Shogo Ito Mobile communications method
KR0180798B1 (ko) * 1993-11-06 1999-03-20 고바야시 요시오 결정성 페니실린 유도체, 그의 제법 및 용도
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE19509697A1 (de) 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5827537A (en) * 1995-05-04 1998-10-27 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
GB9525697D0 (en) * 1995-12-15 1996-02-14 Pharmacia Spa Cephem derivatives
DK0939632T3 (da) 1996-02-23 2006-01-30 Lilly Co Eli Non-peptidyl vasopressin V1a antagonister
US5905076A (en) 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5977090A (en) * 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6054444A (en) * 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
HUP0001062A3 (en) * 1996-09-27 2001-09-28 Guilford Pharmaceuticals Inc B Pharmaceutical compositions of phosphinic acid derivatives having naaladase inhibitor acivity
ID18382A (id) * 1996-09-27 1998-04-02 Guilford Pharm Inc Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase
JP2002507189A (ja) 1997-01-23 2002-03-05 ナエジャ ファーマシューティカル インコーポレーティッド システイン・プロテアーゼ阻害剤としての置換アミノ二環式−β−ラクタムペナムおよびセファム誘導体
WO1998053812A1 (en) * 1997-05-27 1998-12-03 Guilford Pharmaceuticals Inc. Inhibitors of naaladase enzyme activity
AU8140898A (en) * 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
JP2001514375A (ja) 1997-08-22 2001-09-11 パーデュー・リサーチ・ファウンデーション 多重膜擬似親和力を利用する薬物の発見支援
AU2114199A (en) 1998-01-13 1999-08-02 Trustees Of The University Of Pennsylvania, The Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6177421B1 (en) * 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
EP1157275A4 (de) 1999-02-28 2003-01-15 Univ Washington Neue transduktionsmoleküle und verfahren zum benutzen derselben
AU770599B2 (en) * 1999-07-06 2004-02-26 Methylgene Inc. Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
US6426342B2 (en) 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
CA2746824A1 (en) * 1999-08-16 2001-01-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
US6489319B2 (en) 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
FR2811287B1 (fr) * 2000-07-04 2002-10-04 Look Cycle Int Pedale de cycle a positionnement reglable perfectionne
WO2002064147A1 (en) 2001-02-13 2002-08-22 Revaax Pharmaceuticals, Llc Antibiotic compositon and method
WO2002102378A1 (en) * 2001-06-18 2002-12-27 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
BRPI0413908A (pt) 2003-08-25 2006-10-24 Revaax Pharmaceuticals Llc formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo
AU2005272925B2 (en) * 2004-08-13 2011-02-10 Intervet International B.V. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
WO2010127125A1 (en) * 2009-04-29 2010-11-04 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
EP1206261B1 (de) 2006-03-08
EP2305251A3 (de) 2011-05-18
US20040014739A1 (en) 2004-01-22
US20080200447A1 (en) 2008-08-21
AU781218B2 (en) 2005-05-12
CN1382047A (zh) 2002-11-27
CA2380820A1 (en) 2001-02-22
WO2001012184A1 (en) 2001-02-22
EP1206261A2 (de) 2002-05-22
WO2001012171A2 (en) 2001-02-22
ES2258980T3 (es) 2006-09-16
MXPA02001667A (es) 2003-07-14
US6627625B1 (en) 2003-09-30
BR0013366A (pt) 2002-07-23
US20040229857A1 (en) 2004-11-18
ATE319447T1 (de) 2006-03-15
EP1212055A1 (de) 2002-06-12
CA2746824A1 (en) 2001-01-22
DE60026538T2 (de) 2007-02-01
US6610681B1 (en) 2003-08-26
DK1206261T3 (da) 2006-07-03
EP2305251A2 (de) 2011-04-06
WO2001012171A3 (en) 2002-01-17
CA2383522A1 (en) 2001-01-22
US7842683B2 (en) 2010-11-30
JP2011201899A (ja) 2011-10-13
CA2383522C (en) 2011-12-06
NZ517663A (en) 2006-02-24
AU7059800A (en) 2001-03-13
JP2003506490A (ja) 2003-02-18
JP5049437B2 (ja) 2012-10-17
EP1212055B1 (de) 2011-08-03
ATE518540T1 (de) 2011-08-15
EP1212055A4 (de) 2005-09-07
AU6776300A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
AU7888398A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AU7031500A (en) Therapeutic quinazoline compounds
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
PT933995E (pt) Metodo para tratamento de lesao endotelial
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
CA2276606A1 (en) Method of treating prostatic diseases using active vitamin d analogues
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
AU3401093A (en) Therapeutic agent for threatened abortion
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
RU97101420A (ru) Способ лечения тонзиллита
CA2186752A1 (en) Drug treatment of diseased sites deep within the body
UA36252A (uk) Спосіб визначення індивідуальності хворого для вибору адекватної гомеопатичної терапії
RU99122488A (ru) Способ лечения рака эндометрия
EA200000514A1 (ru) Способ лечения эректильной дисфункции

Legal Events

Date Code Title Description
8364 No opposition during term of opposition